

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

SEARCHED SERIALIZED INDEXED DRAWINGS FILED

<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------

EXAMINER

JOHN M. COOPER
1000 DE PAUL
1000 DE PAUL
1000 DE PAUL
1000 DE PAUL

SEARCHED <input type="checkbox"/>	SERIALIZED <input type="checkbox"/>
INDEXED <input type="checkbox"/>	DRAWINGS <input type="checkbox"/>

ART UNIT

PAPER NUMBER

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.	Applicant(s)
	08/907,041	GREENBERGER, JOEL S.
	Examiner Janet Kerr	Art Unit 1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 17 September 1999.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-31 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-31 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are objected to by the Examiner.
 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.
 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.
 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s) _____.
 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)
 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 20) Other: _____

Art Unit: 1633

DETAILED ACTION

The amendment and the petition for suspension of action filed 9-17-99 have been entered.

The request for removal of abandonment status filed 11-13-00 has been entered. Claims 1-31 are pending and under consideration.

Priority

1. It is noted that this application appears to claim subject matter disclosed in prior copending Application No. 08/136,079, filed 10-15-93. A reference to the prior application must be inserted as the first sentence of the specification of this application if applicant intends to rely on the filing date of the prior application under 35 U.S.C. 119(e) or 120. See 37 CFR 1.78(a). Also, the current status of all nonprovisional parent applications referenced should be included.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Art Unit: 1633

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-31 remain rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 5,599,712(A) and is repeated for the reasons of record. Applicant's arguments filed 9-17-99 have been fully considered but they are not persuasive.

Applicant argues that the instant application is directed to methods and pharmaceutical compositions that employ inducible and radioinducible transcriptional regulatory sequences as well as stable integration of the polynucleotide. This is not found persuasive because the claimed invention is drawn to a method for protecting a subject against an agent that elicits free radicals, superoxide anions, or heavy metal cations, said method comprising the steps of administering to said subject a pharmaceutical composition comprising a polynucleotide that encodes a protein transiently expressed in said subject, and said pharmaceutical composition. The claims of '712 are drawn to a method for protecting a **cancer** subject against an agent that elicits free radicals, superoxide anions, or heavy metal cations, said method comprising the steps of administering to said subject a pharmaceutical composition comprising a polynucleotide that encodes a protein transiently expressed in said subject, and said pharmaceutical composition. The claims of the present application clearly encompass the claims of '712. The present invention only specifies the polynucleotide is under the control of an inducible or radioinducible transcriptional regulatory sequence in **claims 17 and 18** but not all of the claims, and only specifies the

Art Unit: 1633

polynucleotide is stably integrated into the genome in the subject in **claim 30** but not all of the claims. Since the polynucleotide is intended to be expressed in the subject, it would have been obvious for one of ordinary skill at the time of the invention to use a regulatory sequence either inducible or not inducible to activate the expression of the polynucleotide in the subject, and the use of inducible or not inducible regulatory sequence depends on the intended targeted tissue(s) or organ(s) of the subject. Further, the integration of the polynucleotide into the genome of the cell of a subject also would have been obvious for one of ordinary skill at the time of the invention because whether the polynucleotide would integrate into the genome of a cell depends on the type of the vector and the component within said vector used. Thus, claims 1-31 remain rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 5,599,712(A).

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-27, and 29-31 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make

Art Unit: 1633

and/or use the invention and is repeated for the reasons of record. Applicant's arguments filed 9-17-99 have been fully considered but they are not persuasive.

Applicant argues that the Office does not provide acceptable evidence or reasoning to support the rejection. This is not found persuasive because of the reasons of record and the Office has provided sufficient evidences and reasoning to support the rejection as indicated in the Official action mailed 3-17-99 (Paper No. 13).

Conclusion

No claim is allowed.

6. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1633

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (703) 305-1678. The examiner can normally be reached on Monday to Friday from 9 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Clark can be reached on (703) 305-4051. The fax phone number for this group is (703) 308-4242.

Questions of formal matters can be directed to the patent analyst, Kimberly Davis, whose telephone number is (703) 305-3015.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Shin-Lin Chen, Ph.D.

Deborah J. R. Clark
DEBORAH J. R. CLARK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600